News
UNCY
6.83
-3.39%
-0.24
Unicycive Therapeutics Publishes Corporate Presentation on Kidney Disease Pipeline and OLC Hyperphosphatemia Program
Reuters · 7h ago
Weekly Report: what happened at UNCY last week (0223-0227)?
Weekly Report · 3d ago
Piper Sandler Remains a Buy on Unicycive Therapeutics (UNCY)
TipRanks · 3d ago
Weekly Report: what happened at UNCY last week (0216-0220)?
Weekly Report · 02/23 09:37
Unicycive Therapeutics management to meet with Piper Sandler
TipRanks · 02/20 14:22
Unicycive Therapeutics (UNCY) Gets a Buy from Westpark Capital
TipRanks · 02/20 06:15
Unicycive Therapeutics initiated with a Buy at WestPark Capital
TipRanks · 02/19 12:57
Unicycive Therapeutics Faces Shareholder Lawsuit Over Alleged False Statements
Reuters · 02/17 14:16
Weekly Report: what happened at UNCY last week (0209-0213)?
Weekly Report · 02/16 09:37
Weekly Report: what happened at UNCY last week (0202-0206)?
Weekly Report · 02/09 09:39
Unicycive Therapeutics Showcases Kidney Disease Drug Pipeline and Launch Plans for OLC
Reuters · 02/06 20:53
Weekly Report: what happened at UNCY last week (0126-0130)?
Weekly Report · 02/02 09:38
Unicycive Therapeutics Showcases Pipeline Advancements in Kidney Disease Treatments
Reuters · 01/30 20:47
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Unicycive Therapeutics (UNCY)
TipRanks · 01/30 14:40
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Phibro Animal Health (PAHC) and Unicycive Therapeutics (UNCY)
TipRanks · 01/30 14:20
Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile
Seeking Alpha · 01/29 21:09
De-Risked Regulatory Path and Commercial Readiness Underpin Buy Rating on Unicycive and Lead Asset OLC
TipRanks · 01/29 17:15
UNICYCIVE THERAPEUTICS INC - FDA ASSIGNS PDUFA TARGET DATE OF JUNE 29, 2026
Reuters · 01/29 14:15
Unicycive Therapeutics Announces FDA Acceptance For Resubmitted Oxylanthanum Carbonate NDA
NASDAQ · 01/29 12:59
Unicycive granted FDA review for resubmitted marketing application for kidney disease drug
Seeking Alpha · 01/29 12:27
More
Webull provides a variety of real-time UNCY stock news. You can receive the latest news about Unicycive Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About UNCY
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.